BioChange Ltd.
Yuval Eitan is an accomplished professional in the fields of biotechnology and biomedical engineering, currently serving as Chief 3D Bioprinting Innovation and Project Manager at BioChange Ltd. since April 2021. Prior to this role, Yuval was the Head of the Molecular Diagnostics Unit at Tissue Diagnostics & Cancer Research from January 2012 to April 2021, and contributed as a research assistant in a nephrology collaboration at Rambam Medical Center in 2011. Academic achievements include a post-doctoral fellowship at the University of Haifa focusing on molecular genetic patterns in post-fire forests and a Ph.D. in biotechnology from the Technion - Israel Institute of Technology, where the research centered on cardiac tissue engineering. Additionally, Yuval developed a specialty biomedical program for junior high school students and holds a B.Sc. in Biotechnology and Food Engineering from the same institution.
This person is not in any offices
BioChange Ltd.
BioChange has developed a breakthrough technology for tissue regeneration. A unique injectable scaffold that stimulates tissue repair and remodelling at the injected site. The scaffold is based on natural biomaterials designed for implantation using a minimally invasive procedure. It mimics the healthy Extra Cellular Matrix (ECM) and triggers the body to repair itself. Multiple long-term animal studies confirmed the safety and efficacy of the technology. The company is now selling products in the veterinary market and in tissue engineering research and is committed to start first clinical study in aesthetic dermatology in 2022. Several other products based on the CellFoam platform technology are in development to enrich our pipeline.